Development of a TMB Assay and the Challenges of Harmonizing across Products
Michael Doherty, Senior Vice President, Head of Product Development, Foundation Medicine, United States
New Challenges of CDX Development into the Commercial Marketplace
Omar Perez, PhD, Head of Precision Medicine and Diagnostics, GlaxoSmithKline, United States
Development of an Integrated Platform for Biomarker and Drug Target Discovery Using Proteomics
Anthony Whetton, Director, Stoller Biomarker Discovery Centre, University of Manchester, United Kingdom
Point-of-Care Diagnostics in Europe – How to Improve Selectivity of Antibiotics Use
Anders Larsson, MD, PhD, Professor, Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, Sweden
Novel Digital PCR and Mutation Enrichment Technologies for the Analysis of Clinically Relevant DNA Alterations in Liquid Biopsies
G. Mike Makrigiorgos, PhD, Professor, Dana Farber Cancer Institute and Harvard Medical School, United States
Liquid Biopsy: The New Diagnostic Concept in Oncology
Klaus Pantel, MD, Professor, Chairman, Institute of Tumor Biology, University Medical Center Hamburg- Eppendorf, Germany